Topics

Companies Related to "Dietary vulnerability found cancer cells with mutated spliceosomes" [Most Relevant Company Matches] [Search Results] RSS

22:15 EST 10th December 2019 | BioPortfolio

Here are the most relevant search results for "Dietary vulnerability found cancer cells with mutated spliceosomes" found in our extensive corporate database of over 50,000 company records.

Showing "Dietary vulnerability found cancer cells with mutated spliceosomes" Companies 1–25 of 4,000+

Relevant

BioCurex Inc.

BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnostics. The technology identifies a cancer marker known as RECAF, which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells.


Onyx Pharmaceuticals

Onyx Pharmaceuticals, Inc. is engaged in the discovery and development of novel therapeutics based upon the genetics of human disease, with an emphasis on cancer. The Company's strategy is to capitalize on the discoveries that have established cancer as a genetic disease. When certain genes are mutated, cells grow and proliferate unchecked and become resistant to internal mechanisms that would nor...

Sensei Biotherapeutics, Inc.

Sensei Biotherapeutics is a privately-held biopharmaceutical company developing immuno-oncology therapies that stimulate the immune system to ‘teach’ it to recognize cancer-specific antigens and attack cancer cells. The company’s patented and proprietary technology platform, called SPIRIT, creates novel therapies that target neoantigens or a...


Genprex, Inc.

Genprex, Inc. is a clinical stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes ...

Minerva Biotechnologies

Minerva Biotechnologies is a pioneer in the field of stem cells and cancer stem cells. Minerva was first to discover that cancer cells hijack an otherwise normal stem cell growth mechanism, involving a growth factor receptor called MUC1* (pronounced muk 1 star). By studying human stem cells in parallel with human cancer cells, Minerva scientists figured ou...

NantKwest Inc.

NantKwest (Nasdaq:NK) is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases. NK cells are the body’s first line of defense due to the innate ability of NK cells to rapidly identify ...

OncoMed Pharmaceuticals Inc.

OncoMed Pharmaceuticals is pioneering the development of novel therapeutics that target a new class of solid tumor cells, known as "cancer stem cells". The company's technology is based on a recent discovery by its co-founders that cancer stem cells are uniquely responsible for the growth and proliferation of tumors. We are leveraging our advanced understanding of cancer stem cells to identify the...

NantKwest

NantKwest (Nasdaq:NK) is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases. NK cells are the body’s first line of defense due to the innate ability of NK cells to rapidly identify ...

NantKwest, Inc.

NantKwest (Nasdaq:NK) is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases. NK cells are the body’s first line of defense due to the innate ability of NK cells to rapidly identify ...

Calithera Biosciences

The direct activation and targeting of caspases represents a novel approach to inducing apoptosis in cancer cells and may have utility across a broad range of cancer types while avoiding chemoresistance. Caspases are the proteases responsible for initiating apoptosis, or programmed cell death, in cancer cells. Cancer cells grow in an uncontrolled manner in part through their ability to develop m...

DirectGene Incorporated

DirectGene was founded in 1999 to develop products in to treat unmet cancer conditions, primarily those of the breast, prostate, and pancreas.The company's technology is based on targeted delivery of genes to kill cancer cells, not repair them. The company accomplishes this by using genes that eliminate cancer cells through either toxicity or the selective replication of adenovirus in the cancer c...

Verastem, Inc.

Verastem, Inc. (NASDAQ: VSTM) is a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: F...

GERDA C. ENDEMANN, PH.D. NUTRITION EDUCATION,COUNSELING,&THERAPY

About my book:"Fat is not the Enemy" The word fat is used to describe both a food component and excess weight in our bodies. Given the negative feelings in our society toward body fat, it is not surprising that we are ready to consider fats in food as unhealthy. Dietary fat has been a scapegoat, unfairly blamed for obesity, heart disease, and cancer. In “Fat is not the Enemy”, I summarize...

Verastem, Inc. Verastem, Inc.

Verastem, Inc. (NASDAQ:VSTM) is discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR a...

CytoSen Therapeutics, Inc.

CytoSen is a private biopharmaceutical company on the front line of advancing clinical development of next generation NK cells with the first scalable, therapeutic platform for high dose, cancer-killing NK cells calibrated to each cancer target while reinforcing immune defenses.

AllCells, LLC

AllCells (www.AllCells.com) is a global biotechnology company founded in 1998 to provide researchers with a reliable supply of biologically relevant, consistent quality primary cells that enable the advancement of scientific research in the areas of cell biology, oncology, virology, hematology, infectious disease and stem cell research. Unlike cell lines, ...

OncoMab™ GmbH

OncoMab™ GmbH's business is the development of human antibodies for the treatment of cancer. The OncoMab™ way is unique because the antibodies are not developed in mice or by genetic engineering, but are isolated directly from cancer patients. The OncoMab™ antibodies are part of the innate natural immunity against malignant cells. This innate immune system functions as the first defence agai...

Targeted Diagnostics and Therapeutics

TDT has emerged as a leader in the development of innovative molecular diagnostics and therapeutics that can improve the quality of life of patients with colorectal cancer and gastrointestinal malignancies. Focused on innovative research and cutting edge technology, TDT has developed highly specific tests to detect colorectal cancer cells in lymph nodes from patients who have undergone surgical st...

OncoMed Pharmaceuticals, Inc.

OncoMed is a clinical development-stage biopharmaceutical company focused on discovering and developing first-in-class monoclonal antibody therapeutics targeting cancer stem cells, or CSCs. Our approach has been to target CSCs, which are the subpopulation of cells in a tumor responsible for driving growth and metastasis of the tumor. CSCs, also known as tumor-initiating cells, exhibit certain pr...

Provectus Pharmaceuticals, Inc.

Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. Its lead oncology agent, PV-10, is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and metastatic liver cance...

Myeloma Canada

Multiple myeloma, a cancer of the bone marrow, is an incurable but treatable disease. The cancer starts in plasma cells, which are produced in the bone marrow. In myeloma, abnormal plasma cells, called myeloma cells, grow uncontrollably, crowding out the normal blood cells in the bone. This can bring on symptoms such as fatigue, recurrent infections and se...

AllCells LLC

AllCells (www.AllCells.com) is a global biotechnology company founded in 1998 to provide researchers with a reliable supply of biologically relevant, consistent quality primary cells that enable the advancement of scientific research in the areas of cell biology, oncology, virology, hematology, infectious disease and stem cell research. Unlike cell lines, ...

StemSave, Inc.

StemSave provides an affordable and non-invasive method for the recovery and cryo-preservation of the powerful Adult Stem Cells found in teeth by teaming up with dentists to harvest stem cells during routine dental procedures. For more information, visit www.StemSave.com.

Tyme, Inc.

Tyme is a pharmaceutical company focused on discovering and developing highly targeted cancer therapeutics for a broad range of oncology indications. Tyme is the originator of what it believes to be a novel, proprietary treatment regimen consisting of a rationally-designed combination of therapeutic agents aimed at exploiting the aberrant metabolic charact...

Tyme Technologies, Inc.

Tyme, Inc. is a pharmaceutical company focused on discovering and developing highly targeted cancer therapeutics for a broad range of oncology indications. Tyme, Inc. is the originator of what it believes to be a novel, proprietary treatment regimen consisting of a rationally-designed combination of therapeutic agents aimed at exploiting the aberrant metab...


More From BioPortfolio on "Dietary vulnerability found cancer cells with mutated spliceosomes"

Quick Search

Corporate Database Quicklinks